Industry News

FDA Approves Daratumumab and Hyaluronidase-fihj for Select Patients with Multiple Myeloma

On July 30, the US Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant. 

For more information read the FDA announcement and the Johnson & Johnson announcement.

Posted 7/31/2024


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
ios-indiana.com
Email Us